Approach to Acute Leukemia

Slides:



Advertisements
Similar presentations
Susanna Akiki WMRGL 2009 Acute Promyelocytic Leukemia with t(15;17) (q22;q21) developing inv(16)(p13q22) secondary AML.
Advertisements

Acute Promyelocytic Leukemia
MALIGNANCIES OF THE HAEMAPOIETIC STEM CELL. Haemapoietic Stem Cell are pluripotent and give rise to all of the haemopoietic cell under the action of cytokines.
LEUKEMIA—HEMATOLOGY {S1}
Acute myeloid leukemia Malignant clonal disorder of immature myeloid progenitor cells characterized by clonal proliferation of abnormal blast cells and.
Leukemias.
Retinoic Acid Receptor Alpha (RARα) Acute Promyelocytic Leukemia (APL)
Acute Leukaemia Dr. Soheir Adam, MRCPath Assistant Professor Department of Haematology, KAUH.
Retinoic Acid Receptor Alpha and Acute Promyelocytic Leukemia Nidhi Thapar April 1, 2004.
Acute myeloid leukemia: morphology and beyond
ACUTE MYELOID LEUKEMIA Irit Avivi
Identification and Diagnosis of the Acute Leukemias
Pei Lin, MD Department of Hematopathology UT M.D. Anderson Cancer Center, Houston, TX Monitoring of Minimal Residual Disease Principles and Applications.
Acute Myeloid Leukemias Diagnosis in The Light of WHO Revisions And Correlation With Risk Adaptive Management ; Case Discussions Dr. Rania Medhat Seliem.
Current Status of Acute Myeloid Leukemia in China Jianxiang Wang Institute of Hematology Hospital of Blood Disease Chinese Academy of Medical Sciences.
ICCS e-Newsletter CSI Fall 2010 David D. Grier, M.D. Department of Pathology. Wake Forest University.
SCIENCE MEETS MEDICINE: ACUTE PROMYELOCYTIC LEUKEMIA Nancy Fuller, M.D. June 23, 2004.
4th Year Medical Student KAU
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,
FDA ODAC AML in Older Individuals Frederick R. Appelbaum, MD May 5, 2005.
Acute Leukemia Kristine Krafts, M.D..
Retinoic Acid Receptor α Acute Promyelocytic Leukemia Michi Nair.
Case 297 Guilin Tang and Sa A. Wang Department of Hematopathology UT MD Anderson Cancer Center.
Case 251: Clinical Information Raymond E Felgar, MD, PhD University of Pittsburgh, Pittsburgh, PA 45-year-old man with recent history of shingles, night.
LEUKEMIA Dr. Omar Alshaer. Acute Leukemia.
Case 255 Elizabeth Courville, MD Robert Hasserjian, MD Massachusetts General Hospital Society for Hematopathology/European Association for Haematopathology.
AML Clinical Presentation. Clinical Presentation: Symptoms Fatigue (50%) Anorexia and weight loss Fever with or without an identifiable infection (10%)
Society for Hematopathology/ European Association for Haematopathology 2013 Workshop Case 145 Nidhi Aggarwal, M.D.; Robert L. Redner, MD; Fiona E. Craig,
(NAAC Accredited ‘A’ grade)
Hematology There are four lectures: 1.Acute leukemias (2 hours). 2.Chronic leukemias (2 hours).
Society for Hematopathology/European Association for Haematopathology 2013 Case Number 208 Erika Moore, MD; Darshan Roy, MD; Patti Cohen, MD; Adam Bagg,
SH/EAHP Workshop 2013 Case 93 Winnie Wu, M.D. Sheeja Pullarkat, M.D.
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
Case 316 Ryan Johnson, MD; Athena Cherry, PhD; Dita Gratzinger, MD, PhD Stanford University Medical Center SH-EAHP October 24, 2013.
Margaret L. Gulley, Thomas C. Shea, Yuri Fedoriw 
Acute Leukemia Kristine Krafts, M.D..
Acute myeloid leukemia
Acute Myeloid Leukemia
Clinical Focus: Acute Promyelocytic Leukemia
Table 1. The French-American-British (FAB) classification of AML
FLT3 Internal Tandem Duplication(ITD) mutation in Acute Myeloid Leukemia and its clincopathological correlation – Study from a tertiary care centre in.
Image 1 Detection of minimal residual disease (MRD) in consecutive bone marrow (BM) samples from a patient with relapse (A) and a patient still in remission.
CHRONIC MYELOID LEUKEMIA (CML)
Early T-Cell Precursor ALL in 5 Year Old Female
17 Chapter 17: Chromosome 17 Nucleus 48,473 bp 882 aa RARA Cytoplasm
STUDY ON FEATURES OF CLINIC, BIOCLINIC AND DIAGNOSIS THE SUBTYPE OF ACUTE LEUKEMIA IN VIETTIEP FRIENDSHIP HOSPITAL, Dr: Pham Thi Loc Hematology.
Misleading acute promyelocytic leukemia morphology
Leukemia Case 1.
Margaret L. Gulley, Thomas C. Shea, Yuri Fedoriw 
Acute Myeloid Leukemia
by Vishal Bhatnagar, and Ashkan Emadi
Case:2 leukemia دينا نعمان جرادة جيهان ايمن مقاط.
Acute leukemia.
Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia
Diagnostic Hematology
by David Grimwade, and Sylvie D. Freeman
A Strong Expression of CD44-6v Correlates With Shorter Survival of Patients With Acute Myeloid Leukemia by S. Legras, U. Günthert, R. Stauder, F. Curt,
Complete remission through blast cell differentiation inPLZF/RARα-positive acute promyelocytic leukemia: in vitro and in vivo studies by Maria C. Petti,
Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia by Jochen Greiner, Yoko Ono, Susanne.
Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia by Parvathi Ranganathan, Xueyan Yu, Caroline Na, Ramasamy Santhanam, Sharon Shacham,
بسم الله الرحمن الرحيم Acute lymphoid leukemia(ALL) Prepared by ::
Donor Cell Leukemia in Umbilical Cord Blood Transplant Patients
Leukemia case (18).
Emerging Importance of Mutational Analysis in Myelodysplastic Syndrome and Acute Myelogenous Leukemia  Aaron T. Gerds, Matthew J. Walter, Bart L. Scott 
HOXB6 overexpression results in delayed AML
Langerhance Cell Histiocytosis (LCH) 5 Years After B-cell Acute Lymphoblastic Leukemia in a 11 year-old boy Professor. Ansari Professor of pediatric hematology.
Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia by Rosemary E. Gale,
Timing for HCT Consultation
by Deogratias Ruhangaza, Andrew G. Evans, and Elizabeth A. Morgan
How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment by Waleed Ghanima, Bertrand Godeau,
Presentation transcript:

Approach to Acute Leukemia Dr. Nikhil Patkar Clinician Scientist & Asst Professor Hematopathology Laboratory Tata Memorial Centre patkarnv@tmc.gov.in

History 59 year old female, easy fatiguability Leucocytosis, decrease in platelets TLC:90,000/mm3 Platelet counts: 54,000/mm3 Suspected to have acute leukemia and referred to TMH

Questions to ask when faced with acute leukemia Is there an increase in blasts or blast equivalents? Are there abnormal promyelocytes? Are there Auer rods? Is cytochemical MPO positive? Is cytochemical NSE positive? Must send for immunophenotyping. YES? NO? NO? NO? NO?

Cytochemical MPO

Summary Morphology Immunophenotype Myeloid Blasts Strong MPO positive CD34 Negative HLA-DR Negative CD13,CD33positive, CD117 dim-negative

Diagnosis?

Questions to ask when faced with acute leukemia Is there an increase in blasts or blast equivalents? Are there abnormal promyelocytes? Are there Auer rods? Is cytochemical MPO positive? Is cytochemical NSE positive? Must send for immunophenotyping. YES? NO? NO? NO? NO?

Is this acute promyelocytic leukemia? Yes / No Is this distinction important? How urgent is the report ?

APL with t(15;17)(q22;q12); PML-RARA

How does this determine treatment? AML with t(15;17) Treated with All Trans Retinoic Acid Or Arsenic Trioxide Excellent survival High mortality if not detected early & treated correctly DIC and bleeding complications eg intracranial bleeding Practical working algorithm in a pathology lab AML M3 or non M3 AML

Overall survival (top) and disease-free survival (bottom) curves of 14 relapsed APL patients after As2O3-induced CR. Overall survival (top) and disease-free survival (bottom) curves of 14 relapsed APL patients after As2O3-induced CR. Shen Z et al. Blood 1997;89:3354-3360 ©1997 by American Society of Hematology

Cup Shaped Blasts Cytochemical MPO Positive

Typical morphology of myeloid blasts with cup-like nuclear invagination in AML. (A) The “cup” seems to be a part of the nucleus in Pappenheim staining, however it is positive for myeloperoxidase (MPO) in reactive blasts. Typical morphology of myeloid blasts with cup-like nuclear invagination in AML. (A) The “cup” seems to be a part of the nucleus in Pappenheim staining, however it is positive for myeloperoxidase (MPO) in reactive blasts. (B) MPO-positive and MPO-negative cup-like blast cells in a patient with AML FAB M1. Kroschinsky F P et al. Haematologica 2008;93:283-286 ©2008 by Ferrata Storti Foundation

Cup shaped blasts are often associated with NPM1 Mutations NPM WT 169bp NPM Mutant 173 bp FLT3-WT 330bp

NPM1 Mutated AML, FAB AML M1 Final Diagnosis NPM1 Mutated AML, FAB AML M1